0000899243-21-007207.txt : 20210218
0000899243-21-007207.hdr.sgml : 20210218
20210218191832
ACCESSION NUMBER: 0000899243-21-007207
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210201
FILED AS OF DATE: 20210218
DATE AS OF CHANGE: 20210218
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BOLNO PAUL
CENTRAL INDEX KEY: 0001657710
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37627
FILM NUMBER: 21651388
MAIL ADDRESS:
STREET 1: C/O WAVE LIFE SCIENCES LTD.
STREET 2: 733 CONCORD AVE.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Wave Life Sciences Ltd.
CENTRAL INDEX KEY: 0001631574
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: U0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7 STRAITS VIEW
STREET 2: #12-00, MARINA ONE EAST TOWER
CITY: SINGAPORE
STATE: U0
ZIP: 018936
BUSINESS PHONE: 617-949-2900
MAIL ADDRESS:
STREET 1: 733 CONCORD AVENUE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
FORMER COMPANY:
FORMER CONFORMED NAME: WAVE Life Sciences Ltd.
DATE OF NAME CHANGE: 20170516
FORMER COMPANY:
FORMER CONFORMED NAME: Wave Life Sciences Ltd.
DATE OF NAME CHANGE: 20151106
FORMER COMPANY:
FORMER CONFORMED NAME: Wave Life Sciences LTD.
DATE OF NAME CHANGE: 20151106
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-01
0
0001631574
Wave Life Sciences Ltd.
WVE
0001657710
BOLNO PAUL
C/O WAVE LIFE SCIENCES LTD.,
733 CONCORD AVE.
CAMBRIDGE
MA
02138
1
1
0
0
President and CEO
Ordinary Shares
2021-02-01
4
A
0
150000
0.00
A
422181
D
Ordinary Shares
2021-02-16
4
S
0
11205
10.57
D
410976
D
Share Option (right to buy)
10.48
2021-02-01
4
A
0
200000
0.00
A
2031-02-01
Ordinary Shares
200000
200000
D
Consists of restricted share units (RSUs). The RSUs vest in two equal installments on February 15, 2022 and February 15, 2023.
On February 16, 2021, the reporting person sold 11,205 ordinary shares solely to cover taxes associated with the vesting of RSUs on February 15, 2021. These sales were made pursuant to a 10b5-1 Trading Plan.
The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $10.47 to $10.58 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
The option vests as to 50% of the shares on February 15, 2022 and 50% on February 15, 2023.
/s/ Paul B. Bolno
2021-02-18